Avoiding Common Pitfalls in the IND and CTA Submission Process

[Fill out the form below to register]

Abstract: When planning an Investigational New Drug (IND) or Clinical Trial Authorization (CTA) submission, navigating FDA, EMA, and other regulations can be challenging and creating scientifically-sound strategies are essential. As submissions expand to multiple countries during later phase trials, greater challenges can arise if not prepared with knowledge of the requirements, proper time management, and defined roles for the team towards approval. 

Join us as experts in project management, medical writing, and regulatory operations discuss best practices for a successful submission process from start to finish. 

Attendees will learn:

  • Efficiencies for multi-country submissions 
  • Essential steps in pre-submission planning 
  • Timeline management and potential pitfalls 
  • How to define roles and responsibilities to avoid delays or confusion 
  • Structure and content of the submissions at various stages of development 
  • Navigating the country–specific regulatory requirements 
  • Post-submission maintenance and responsibilities 

Presenters:

Jessica Reed, PhD, Senior Manager, Project and Account Management  

Nicole Northrop, PhD, Manager, Regulatory and Medical Writing 

Allison Ward, MSA, MSEd, Senior Manager, Regulatory Operations 

Avoiding Common Pitfalls in the IND and CTA Submission Process

Register for the webinar

Suggested For You

perspectives

June 17th, 2025

Solving Data Complexity with Real-Time Insights, Predictive AI, and Smarter Decision-Making with Datacise

perspectives

June 10th, 2025

Applying Artificial Intelligence (AI) and Real-World Evidence to Boost Efficiency in Patient Safety Narratives 

perspectives

June 3rd, 2025

Choosing the Right Strategy: Parallel, Sequential, and Staggered Regulatory Submissions 

perspectives

May 28th, 2025

A Season of Change: Why the REMS Industry Consortium Matters More Than Ever

perspectives

May 20th, 2025

Navigating FDA OMOR Meetings: A Comprehensive Guide to Type X, Y, and Z Meetings for OTC Drug Sponsors

perspectives

May 6th, 2025

Why Clinical Trial Simulation Is Reshaping Drug Development: A Q&A with Dr. Aiden Flynn

perspectives

April 24th, 2025

How to Derisk Clinical Development with Unified Trial Design and Regulatory Strategy

perspectives

April 8th, 2025

Updated UK Clinical Trial Regulation: The Key Changes and Impact on Development Safety Update Report (DSUR) Requirements

perspectives

March 27th, 2025

Enhancing Drug Safety Through Digital Solutions: Innovative Technologies in FDA REMS Programs

perspectives

March 6th, 2025

Overview of FDA Guidance for Industry on Assessment of Ovarian Toxicity in Premenopausal Adults During Development for Oncologic Products

perspectives

February 13th, 2025

Helping European Drug Development Companies Succeed in the US Market

perspectives

January 30th, 2025

Post-PDUFA VII Updates: FDA Meetings Public Workshop & Lessons Learned